Home  »  Companies   »  Allogene Therapeutics Inc. (NASDAQ: ALLO) Fell -0....

Allogene Therapeutics Inc. (NASDAQ: ALLO) Fell -0.36%, Now What? Don’t Panic

Allogene Therapeutics Inc. (NASDAQ:ALLO) price on Friday, March 17, fall -0.36% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.49.

A look at the stock’s price movement, the close in the last trading session was $5.51, moving within a range at $5.30 and $5.56. The beta value (5-Year monthly) was 0.77. Turning to its 52-week performance, $17.49 and $5.36 were the 52-week high and 52-week low respectively. Overall, ALLO moved -24.07% over the past month.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Allogene Therapeutics Inc.’s market cap currently stands at around $805.77 million, with investors looking forward to this quarter’s earnings report slated for May 02, 2023 – May 08, 2023. Analysts project the company’s earnings per share (EPS) to be -$0.7, which has seen fiscal year 2022 EPS growth forecast to increase to -$2.37 and about -$2.74 for fiscal year 2023. Per the data, EPS growth is expected to be -25.40% for 2023 and -15.60% for the next financial year.

The average forecast suggests up to a 17.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2022 to grow to $190k, representing a -99.50% decline on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ALLO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

ALLO’s current price about -10.86% and -18.20% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 28.99, while 7-day volatility ratio is 5.97% and 6.23% in the 30-day chart. Further, Allogene Therapeutics Inc. (ALLO) has a beta value of 0.81, and an average true range (ATR) of 0.38.

In the market, a comparison of Allogene Therapeutics Inc. (ALLO) and its peers suggest the former has performed considerably weaker. Data shows ALLO’s intraday price has changed -0.36% in last session and -34.56% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -1.07% on the day and only -12.69% in the past 12 months. Looking at another peer, we see that AbbVie Inc. (ABBV) price has dipped -0.70% on the day. However, the stock is -1.17% off its price a year ago. Moreover, Pfizer Inc. (PFE) is also down -0.67% in trading on the day while keeping a a downtrend of -24.23% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.

If we refocus on Allogene Therapeutics Inc. (NASDAQ:ALLO), historical trading data shows that trading volumes averaged 2.41 million over the past 10 days and 1.91 million over the past 3 months. The company’s latest data on shares outstanding shows there are 144.16 million shares.

The 0.60% of Allogene Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 76.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 34.41 million on Jan 30, 2023, giving us a short ratio of 16.72. The data shows that as of Jan 30, 2023 short interest in Allogene Therapeutics Inc. (ALLO) stood at 23.86% of shares outstanding, with shares short rising to 33.43 million registered in Dec 29, 2022. Current price change has pushed the stock -12.72% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALLO stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *